84 related articles for article (PubMed ID: 23595984)
21. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
[TBL] [Abstract][Full Text] [Related]
22. Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens.
Solomon A; Gupta PK; LiVolsi VA; Baloch ZW
Diagn Cytopathol; 2002 Sep; 27(3):143-8. PubMed ID: 12203860
[TBL] [Abstract][Full Text] [Related]
23. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
[TBL] [Abstract][Full Text] [Related]
25. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
26. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
27. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
28. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
29. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
30. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
31. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
32. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
[TBL] [Abstract][Full Text] [Related]
33. BRAF mutations in an Italian cohort of thyroid cancers.
Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
[TBL] [Abstract][Full Text] [Related]
34. Tall-cell variant of papillary thyroid cancer: disregarded entity?
Rüter A; Nishiyama R; Lennquist S
World J Surg; 1997 Jan; 21(1):15-20; discussion 20-1. PubMed ID: 8943172
[TBL] [Abstract][Full Text] [Related]
35. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival.
Morris LG; Shaha AR; Tuttle RM; Sikora AG; Ganly I
Thyroid; 2010 Feb; 20(2):153-8. PubMed ID: 20151822
[TBL] [Abstract][Full Text] [Related]
36. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer.
Vannucchi G; De Leo S; Perrino M; Rossi S; Tosi D; Cirello V; Colombo C; Bulfamante G; Vicentini L; Fugazzola L
Eur J Endocrinol; 2015 Jul; 173(1):29-36. PubMed ID: 25862786
[TBL] [Abstract][Full Text] [Related]
37. Tall cell papillary carcinoma of the thyroid: metastatic to the pancreas.
Jobran R; Baloch ZW; Aviles V; Rosato EF; Schwartz S; LiVolsi VA
Thyroid; 2000 Feb; 10(2):185-7. PubMed ID: 10718557
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implications of the tall cell variant of papillary thyroid carcinoma.
Johnson TL; Lloyd RV; Thompson NW; Beierwaltes WH; Sisson JC
Am J Surg Pathol; 1988 Jan; 12(1):22-7. PubMed ID: 3337337
[TBL] [Abstract][Full Text] [Related]
39. Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid.
Ostrowski ML; Merino MJ
Am J Surg Pathol; 1996 Aug; 20(8):964-74. PubMed ID: 8712296
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of p53 in tall cell variants of papillary thyroid carcinoma.
Rüter A; Dreifus J; Jones M; Nishiyama R; Lennquist S
Surgery; 1996 Dec; 120(6):1046-50. PubMed ID: 8957493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
